Extracellular Vesicles May Predict Response to Radioembolization and Sorafenib Treatment in Advanced Hepatocellular Carcinoma: An Exploratory Analysis from the SORAMIC Trial
Year: 2022
Type: article
Abstract: PURPOSE: SORAMIC is a randomized controlled trial in patients with advanced hepatocellular carcinoma (HCC) undergoing sorafenib ± selective internal radiation therapy (SIRT). We investigated the value of extracellular vesicle (EV)-based proteomics for treatment response prediction. EXPERIMENTAL DESIGN: The analysis population comprised 25 patients receiving SIRT+sorafenib and 20 patients receiving sorafenib alone. Patients were classified as responders or nonresponders based on changes in AFP and imaging or overall survival. Proteomic analysis was performed on plasma EVs by LC/MS, followed by bioinformatics analysis. Clinical relevance of candidate EV proteins was validated by survival and receiver-operating characteristic analysis with bootstrap internal sampling validation. Origin of circulating EV was explored by IHC staining of liver and tumor tissues and transcriptomics of blood cells. RESULTS: Proteomic analysis identified 56 and 27 EV proteins that were differentially expressed in plasma EVs between responders and nonresponders receiving SIRT+sorafenib and sorafenib alone, respectively. High EV-GPX3/ACTR3 and low EV-ARHGAP1 were identified as candidate biomarkers at baseline from the 13 responders to SIRT+sorafenib with statistically significant AUC = 1 for all and bootstrap P values 2.23 × 10-5, 2.22 × 10-5, and 2.23 × 10-5, respectively. These patients showed reduced abundance of EV-VPS13A and EV-KALRN 6 to 9 weeks after combined treatment with significant AUC and bootstrap P values. In reverse, low GPX3 and high ARHGAP1 demonstrated better response to sorafenib monotherapy with AUC = 0.9697 and 0.9192 as well as bootstrap P values 8.34 × 10-5 and 7.98 × 10-4, respectively. HCC tumor was the likely origin of circulating EVs. CONCLUSIONS: In this exploratory study, EV-based proteomics predicted response to SIRT+sorafenib and sorafenib-only treatment in patients with advanced HCC of metabolic origin.
Source: Clinical Cancer Research
Authors: Timothy Wai Ho Shuen(Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Supervision, Validation, Visualization, Writing – original draft), Marianna Alunni-Fabbroni(Conceptualization, Formal analysis, Supervision, Writing – original draft, Writing – review & editing), Elif Öcal(Formal analysis, Writing – original draft, Writing – review & editing), Peter Malfertheiner(Conceptualization, Formal analysis, Funding acquisition, Writing – review & editing), Moritz Wildgruber(Conceptualization, Formal analysis, Writing – review & editing), Regina Schinner(Data curation, Formal analysis, Writing – review & editing), Maciej Pech(Data curation, Formal analysis, Project administration, Writing – review & editing), Julia Benckert(Data curation, Formal analysis, Writing – review & editing), Bruno Sangro(Data curation, Formal analysis, Project administration, Writing – review & editing), Christiane Kuhl(Data curation, Formal analysis, Project administration, Writing – review & editing), Antonio Gasbarrini(Data curation, Formal analysis, Project administration, Writing – review & editing), Pierce Kah Hoe Chow(Data curation, Formal analysis, Project administration, Writing – review & editing), Han Chong Toh(Conceptualization, Data curation, Formal analysis, Project administration, Supervision, Writing – original draft, Writing – review & editing), Jens Ricke(Conceptualization, Data curation, Formal analysis, Funding acquisition, Project administration, Supervision, Writing – original draft, Writing – review & editing)
Institutions: National Cancer Centre Singapore, LMU Klinikum, Ludwig-Maximilians-Universität München, Otto-von-Guericke-Universität Magdeburg, Charité – Universitätsmedizin Berlin, Clinica Universidad de Navarra, Universitätsklinikum Aachen, RWTH Aachen University, Università Cattolica del Sacro Cuore, Agostino Gemelli University Polyclinic, National University of Singapore, Singapore General Hospital, SingHealth Duke-NUS Academic Medical Centre, Duke-NUS Medical School
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
Award: G209277924
OpenAlex ID: W4283662815
